Eckert & Ziegler stock gains modestly as investors focus on recent results

Published on 09/07/2026 at 09:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock is trading slightly higher compared with its recent range, while investors focus on the company’s latest reported figures and its role as a specialized radiation technology supplier.

Photorealistischer Reinraum einer radiopharmazeutischen Produktionsanlage — Eckert & Ziegler DE0005659700 Medizintechnik: Forscher arbeiten in modernem Radiopharmazeutika-Reinraum mit Gloveboxen und Hot-Cells, Illustration mit AI erstellt.

Eckert & Ziegler stock (ISIN DE0005659700) is trading modestly above its recent levels as of September 7, 2026, with the share price around the 15 euro mark on a German trading venue and a small single-digit percent gain versus the previous session.

Stock moves within recent trading range

On the German market, Eckert & Ziegler shares are quoted close to 15.04 euros, which represents a gain of about 2.3 percent compared with a recent reference level reported for the stock in the current European trading environment as of early September 2026.

This price moves within a typical short-term range and keeps the stock clearly below typical mid-cap benchmarks in terms of valuation multiples, while still reflecting the company’s established position in niche radiation technology.

Recent reported figures frame the investment case

According to recent company and market data for Eckert & Ziegler, the most up to date published financial figures available to investors in 2026 are the latest interim and annual numbers that show the group generating revenue in the low hundreds of millions of euros and solid profitability, although exact current-half figures are not yet visibly reported beyond previous periods.

Historical: in an earlier fiscal year before 2024, Eckert & Ziegler reported annual revenue in the low hundreds of millions of euros and a net profit in the tens of millions of euros, giving an indicative net margin in the high single-digit to low double-digit percent range, which serves mainly as a comparison point rather than a current performance measure.

Go deeper

More on Eckert & Ziegler stock

Background information, older results and additional news on Eckert & Ziegler can be found in the issuer overview and investor materials.

All Eckert & Ziegler news Investor Relations

Radiopharma and isotope products as core business

Eckert & Ziegler focuses on radioactive components and related equipment for medical and industrial applications, including sealed radiation sources and products for nuclear medicine, brachytherapy and imaging.

The company’s radiopharma and isotope solutions are used by hospitals and laboratories worldwide to diagnose and treat cancer and other serious diseases, which makes the robustness of long-term demand more important to investors than short-term price swings.

Stock remains supported around the 15-euro level

As of September 7, 2026, Eckert & Ziegler stock is holding close to 15.04 euros on a German trading venue, which places the share roughly in the middle of its recent multi-month chart corridor and reflects a moderate premium to some older trading lows recorded earlier in the year.